Nurix Therapeutics Will Present Preclinical Data From NX-5948, Currently In Phase 1b For B-Cell Malignancies And In IND-Enabling Studies For Autoimmune Disease, And GS-6791/NX-0479 In Collaboration With Gilead Sciences And Also In IND-enabling...

nurix therapeutics將發佈來自NX-5948的臨床前數據，目前處於面向b-細胞惡性腫瘤的10億階段，並在自身免疫性疾病的IND啓用研究中，與吉利德科學合作的GS-6791/NX-0479，同時也處於IND啓用研究階段...

Benzinga · 10/09 19:24

Nurix Therapeutics Will Present Preclinical Data From NX-5948, Currently In Phase 1b For B-Cell Malignancies And In IND-Enabling Studies For Autoimmune Disease, And GS-6791/NX-0479 In Collaboration With Gilead Sciences And Also In IND-enabling Studies, At The American College Of Rheumatology Convergence 2024

nurix therapeutics將在美國風溼病學會2024年會上發佈NX-5948的臨床前數據，該藥目前處於10億階段，用於b-細胞惡性腫瘤，並在自身免疫疾病的IND啓動研究中，並與吉利德科學合作的GS-6791/NX-0479也在IND啓動研究中。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。